Acumen Pharmaceuticals secures $35M for brain-delivery platform as Alzheimer’s trial reaches key milestone
Acumen Pharmaceuticals (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel targeted immunotherapy for Alzheimer’s disease, today reported financial results for the full year ended December 31, 2025, and provided a comprehensive business update.










